Most Popular in:
Medical Esthetics Treatments
Celecoxib Shown to Prevent Nonmelanoma Skin Cancers
Posted: December 21, 2010
Celecoxib (also known by its brand name Celebrex) may help prevent nonmelanoma skin cancers in patients with extensive actinic keratosis, which is often a precursor to these cancers, according to a randomized clinical trial published online November 29 in The Journal of the National Cancer Institute.
Nonmelanoma skin cancers—including cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs)—are among the most common cancers in the United States. The incidence of these malignancies is rising and is beginning to occur more frequently in young adults. Exposure to UV radiation is believed to be one of the main causes. Existing methods of protecting against UV light, namely sunscreens, have only been modestly effective at reducing these cancers' incidence, so researchers have begun looking for other ways to prevent them. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits the enzyme cyclooxygenase 2, believed to be involved in the development of UV-induced nonmelanoma skin cancers.
To determine whether celecoxib reduces the incidence of new actinic keratosis, Craig A. Elmets, MD, of the University of Alabama at Birmingham, and colleagues, conducted a double-blind, placebo-controlled randomized trial with 240 people with actinic keratoses, or precancerous skin lesions. They looked at the number of new lesions after three, six and nine months of therapy and at two months following the completion of therapy.
The researchers found that the number of new precancerous lesions in the group of people taking celecoxib and those taking the placebo was the same. However, by the end of the trial, those taking celecoxib had a statistically significant fewer number of nonmelanoma skin cancers compared with those in the placebo group.
The researchers write, "The findings of this study, which showed that the celecoxib-treated individuals developed fewer nonmelanoma skin cancers than placebo-treated individuals, suggest that cyclooxygenase inhibitors may provide an additional benefit to sunscreens in the prevention of nonmelanoma skin cancers."